Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China’s Tasly Mixes Western Drug-Making Art With Herbal Work

This article was originally published in PharmAsia News

Executive Summary

China's Tianjin Tasly Pharmaceutical relies on the accepted methods of manufacturing chemical-based pharmaceuticals for use in the herbal medicine market. Tasly's Fufang Danshen Diwan pill for emergency coronary treatment was the first herbal treatment cleared by the U.S. FDA for clinical trials and accounted for $80 million of the firm's sales last year. The firm's leaders attribute the success to the firm's use of production and presentation methods, research into a medicine's molecular formula and other R&D work to make its wares more acceptable in the U.S. and European markets. (Click here for more



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts